Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE. Mittendorf EA, et al. Among authors: stojadinovic a. Cancer. 2012 May 15;118(10):2594-602. doi: 10.1002/cncr.26574. Epub 2011 Oct 11. Cancer. 2012. PMID: 21989902 Free PMC article. Clinical Trial.
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Amin A, et al. Among authors: stojadinovic a. Cancer Immunol Immunother. 2008 Dec;57(12):1817-25. doi: 10.1007/s00262-008-0509-2. Epub 2008 Apr 8. Cancer Immunol Immunother. 2008. PMID: 18392824 Free PMC article. Clinical Trial.
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Holmes JP, et al. Among authors: stojadinovic a. Cancer. 2008 Oct 1;113(7):1666-75. doi: 10.1002/cncr.23772. Cancer. 2008. PMID: 18726994 Free article. Clinical Trial.
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Benavides LC, et al. Among authors: stojadinovic a. Clin Cancer Res. 2009 Apr 15;15(8):2895-904. doi: 10.1158/1078-0432.CCR-08-1126. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351776 Clinical Trial.
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE. Holmes JP, et al. Among authors: stojadinovic a. Cancer. 2011 Feb 1;117(3):463-71. doi: 10.1002/cncr.25586. Epub 2010 Sep 15. Cancer. 2011. PMID: 20845479 Free article. Clinical Trial.
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE. Gates JD, et al. Among authors: stojadinovic a. Vaccine. 2010 Nov 3;28(47):7476-82. doi: 10.1016/j.vaccine.2010.09.029. Epub 2010 Sep 19. Vaccine. 2010. PMID: 20858449 Clinical Trial.
Monitoring circulating tumor cells in cancer vaccine trials.
Gates JD, Benavides LC, Stojadinovic A, Mittendorf EA, Holmes JP, Carmichael MG, McCall S, Milford AL, Merrill GA, Ponniah S, Peoples GE. Gates JD, et al. Among authors: stojadinovic a. Hum Vaccin. 2008 Sep-Oct;4(5):389-92. doi: 10.4161/hv.4.5.6115. Epub 2008 Sep 16. Hum Vaccin. 2008. PMID: 18437056
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Hueman MT, et al. Among authors: stojadinovic a. Cancer Immunol Immunother. 2007 Feb;56(2):135-46. doi: 10.1007/s00262-006-0188-9. Epub 2006 Jun 17. Cancer Immunol Immunother. 2007. PMID: 16783576 Free PMC article. Clinical Trial.
276 results